GP
GreenPower Motor Company Inc.
There isn't enough reported data to score GP yet.
LCID
Lucid Group, Inc.
LCID lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
GP Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Weak | |
| Unavailable |
GP's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
GP PE Valuation
GP has no meaningful PE right now: it lost money over the past year.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
GP Forward outlook
There aren't enough analyst estimates for GP to show an outlook.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
GP Earnings Per Share
GP and LCID do not have enough comparable growth data to identify a winner.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
GP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $439.1K | -72% |
| Q1 2026 | $3.9M | -10% |
| Q4 2025 | $8.5M | +18% |
| Q3 2025 | $2.5M | -53% |
| Q2 2025 | $1.5M | -48% |
| Q1 2025 | $4.3M | -16% |
| Q4 2024 | $7.2M | -12% |
| Q3 2024 | $5.3M | -37% |
GP's revenue has slid since its 2023 peak: $439,148 last quarter, down 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -367% | -136 points |
| Q1 2026 | 1.7% | +129 points |
| Q4 2025 | 58% | N/A |
| Q3 2025 | -118% | N/A |
| Q2 2025 | -231% | N/A |
| Q1 2025 | -127% | N/A |
| Q4 2023 | -53% | -30 points |
| Q3 2023 | -47% | -7.3 points |
GP's operating margin was −367% last quarter, down 136 points from the same quarter a year ago, near the bottom of its range since 2019.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over GP on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID has the edge over GP on profitability, with a higher operating margin.
GP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$1.3M | +$111.7K |
| Q1 2026 | -$3.7M | -$3.3M |
| Q4 2025 | -$1.2M | -$131.2K |
| Q3 2025 | $173.2K | +$1.5M |
| Q2 2025 | -$1.4M | +$1.9M |
| Q1 2025 | -$390.8K | +$4.6M |
| Q4 2024 | -$1.1M | -186% |
| Q3 2024 | -$1.4M | +$4.1M |
GP has the edge over LCID on cash flow, with more consistent year-over-year improvement.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
GP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +99% | +562K shares |
| 1 year | +127% | +633K shares |
GP has 1M diluted shares, up 127% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2023 | — |
| Q3 2023 | — |
GP hasn't bought back shares in the past year.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has the edge over GP on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
GP Net Leverage
GP's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
GP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.6 | Neutral |
| Stochastic | 3.8 | Oversold |
GP's weekly RSI is 31 (neutral) and its Stochastic is 4 (oversold).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
GP PE vs Consumer Cyclical Sector
GP has no meaningful PE right now: it lost money over the past year.
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
GP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.70 | 28% below |
| 20 week MA | $4.72 | 74% below |
| 50 week MA | $5.04 | 76% below |
| 100 week MA | $14.0 | 91% below |
| 200 week MA | $64.0 | 98% below |
GP is in a downtrend: it's below all five of its weekly moving averages, and 98% below its 200-week average.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
GP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $76.7 | $1,134.5 | +1380% |
| 2021 | $1,134.5 | $443.0 | -61% |
| 2022 | $443.0 | $96.5 | -78% |
| 2023 | $96.5 | $156.5 | +62% |
| 2024 | $156.5 | $37.9 | -76% |
| 2025 | $37.9 | $4.17 | -89% |
| 2026 YTD | $4.17 | $1.23 | -71% |
GP has the edge over LCID on returns for 2026, with the stronger performance.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.